Internists testify about rising prescription drug prices and their impact on patients

June 21, 2016

The American College of Physicians (ACP) today provided physician perspective on the escalating cost of prescription drugs, the impact of the costs on internal medicine physicians and their patients, and support for the intent of the bipartisan Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016 to reduce anti-competitive practices.

Testifying before the Senate Committee on the Judiciary, Subcommittee on Antitrust, Competition Policy and Consumer Rights, Nitin S. Damle, MD, MS, FACP, president of ACP, an assistant professor of medicine at Brown University, and a practicing internal medicine physician, spoke on behalf of ACP's 143,000 members.

"ACP recognizes that ensuring and improving patient access to prescription drugs is a growing need," Dr. Damle said. "Over the past several years, we have seen a dramatic rise in the cost of prescription drugs in this country. These increases apply not only to specialty drugs that treat life-threatening illness like cancer, but also common drugs like antibiotics that treat bacterial infections. That, coupled with several recent high-profile price gauging cases, has vaulted the issue of rising prescription drug costs into the forefront of our everyday conversations, including among those in Congress."

ACP strongly supports using multiple approaches--such as cost and price transparency, greater flexibility for public programs to leverage volume purchasing, and encouraging competition, among others--to stem the increasing cost of prescription drugs, Dr. Damle noted. In fact, ACP recently developed a series of specific positions and recommendations that were published just three months ago in in its position paper on escalating drug prices, "Stemming the Escalating Cost of Prescription Drugs." ACP supports policies and proposals that give patients the best available information and access to prescription medications at the lowest cost possible, while acknowledging the need for a strong pharmaceutical market that fosters investment in and development of new treatments.

"ACP believes it is important that policies addressing the increase in prescription drug prices cover not only new entrants to the market, but also drugs that have been on the market and may be generic or single-source drugs," Dr. Damle emphasized.

Dr. Damle told the subcommittee about experiences from his own practice, teaching and from colleagues from around the country he's talked to as ACP president. "I see firsthand the choices that patients must make about their health." "These examples from just one day in my office are repeated day in and day out," Dr. Damle said. "Advances in medicine have been lifesaving but they need to be affordable to society. Non-compliance with medication regimens can lead to more serious health complications, more patients suffering from disease and more costs to society. The pharmaceutical industry needs a reasonable return on investment but there needs to be a balance between profits and the service they provide in treating and maintaining the health of our patients."

Dr. Damle concluded his remarks by expressing appreciation to the Subcommittee for asking for input from the physician community during introduction of the CREATES Act. "Our hope is that the information shared today will give that provider perspective. We stand ready to continue to serve as a resource and welcome the opportunity to continue to work with you as you continue to advance this bill through the 114th Congress.
The American College of Physicians is the largest medical specialty organization and the second-largest physician group in the United States. ACP members include 143,000 internal medicine physicians (internists), related subspecialists, and medical students. Internists specialize in the prevention, detection, and treatment of illness in adults. Follow ACP on Twitter and Facebook.

American College of Physicians

Related Rheumatoid Arthritis Articles from Brightsurf:

Reducing dementia in patients with rheumatoid arthritis
The incidence of dementia in patients with rheumatoid arthritis is lower in patients receiving biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) than in patients who receive conventional synthetic DMARDs, according to a new study.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Rheumatoid arthritis patients under treatment with methotrexate
Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).

Rheumatoid arthritis -- can its onset be delayed or prevented?
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that leads to significant health issues as well as high treatment costs.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Rheumatoid arthritis meets precision medicine
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study.

Read More: Rheumatoid Arthritis News and Rheumatoid Arthritis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to